Camp4 Therapeutics Corp SEC filings CAMP
Camp4 Therapeutics Corp has 192 filings in SEC EDGAR's recent list, going back to Sep 25, 2018. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K | Current report | Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| EFFECT | Filing | Aug 12, 2026 | — |
| 424B3 | Prospectus | Aug 12, 2026 | — |
| S-3 | Shelf registration | Aug 6, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 24, 2026 | Mar 18, 2026 |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2026 | Jan 9, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Dec 23, 2025 | Dec 22, 2025 |
| 8-K |
Current report
Material agreement
|
Dec 18, 2025 | Dec 18, 2025 |
| 424B5 | Prospectus supplement | Dec 18, 2025 | — |
| FWP | Free writing prospectus | Dec 18, 2025 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 18, 2025 | Dec 17, 2025 |
| 424B5 | Prospectus supplement | Dec 1, 2025 | — |
| 424B3 | Prospectus | Nov 25, 2025 | — |
| S-3 | Shelf registration | Nov 10, 2025 | — |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| S-3 | Shelf registration | Nov 3, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2025 | Oct 1, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Sep 10, 2025 | Sep 9, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2025 | Aug 14, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 16, 2025 | May 16, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| ARS | Annual report to shareholders | Apr 30, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 11, 2025 |
| S-8 | Employee stock plan registration | Mar 27, 2025 | — |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Officer or director change
|
Mar 18, 2025 | Mar 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 7, 2025 | Jan 7, 2025 |
| 10-Q | Quarterly report | Nov 21, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 21, 2024 | Nov 21, 2024 |
| SEC STAFF LETTER | Filing | Oct 16, 2024 | — |
| S-8 | Employee stock plan registration | Oct 16, 2024 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 15, 2024 | Oct 15, 2024 |
| 424B4 | Prospectus | Oct 11, 2024 | — |
| EFFECT | Filing | Oct 10, 2024 | — |
| CERT | Filing | Oct 10, 2024 | — |
| 8-A12B | Form 8-a12b | Oct 8, 2024 | — |
| CORRESP | Letter to the SEC | Oct 8, 2024 | — |
| CORRESP | Letter to the SEC | Oct 8, 2024 | — |
| S-1/A | Amended registration statement | Oct 7, 2024 | — |
| CORRESP | Letter to the SEC | Oct 2, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 2, 2024 | — |
| S-1/A | Amended registration statement | Sep 26, 2024 | — |
| S-1 | Registration statement | Sep 20, 2024 | — |
| DRSLTR | Filing | Aug 22, 2024 | — |
| DRS/A | Filing | Aug 22, 2024 | — |
| SEC STAFF LETTER | Filing | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2024 | — |
| DRS/A | Filing | Aug 2, 2024 | — |
| DRSLTR | Filing | Jul 26, 2024 | — |
| DRS/A | Filing | Jul 26, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 15, 2024 | — |
| DRS | Filing | Jun 14, 2024 | — |
| D | Filing | Jun 21, 2022 | — |
| D/A | Filing | Oct 29, 2021 | — |
| D | Filing | Mar 19, 2021 | — |
| D | Filing | Sep 25, 2018 | — |
Showing 78 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CAMP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1736730
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.